1. Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI Team* *Xue Hua, Jon Morra, Alex Leow, Yi-Yu Chou, Suh Lee, April Ho, Christina Avedissian, Sarah Madsen, Igor Yanovsky, Boris Gutman, Liana Apostolova, Arthur Toga, et al. *Google “paul thompson ADNI” to get a webpage with links to the full papers (PDFs)

2. Overview Mapped brain changes in 676 ADNI subjects
Tensor-based morphometry (gives 3D maps of rates of tissue loss)
Automated Hippocampal/Ventricular Mapping
1000s of scans, no manual intervention
Only need ~40 AD and 80 MCI subjects to detect 25% slowing of disease (10x better than best clinical score)
Which MRI measures correlate best with clinical decline, and with CSF biomarkers (A-beta/Tau)?
What is the best numeric summary of change from a 3D image?
Is 3T better than 1.5T? How is power affected by pooling?

3. WHAT ARE THE SUBTLEST BRAIN CHANGES WE CAN DETECT?

7. Single Subject - Rates of Atrophy mapped with TBM

8. AD (N=104) versus Normal (N=157) - Mean Atrophy Rates -
Hua, X. and Thompson, P.M. et al., 2009 8

9. MCI (N=254) versus Normal (N=157) - Mean Atrophy Rates -
Hua, X. and Thompson, P.M. et al., 2009

10. AD (N=104) versus Normal (N=157) - Mean Atrophy Rates -
Hua, X. and Thompson, P.M. et al., 2009

11. MCI (N=254) versus Normal (N=157) - Mean Atrophy Rates -
Hua, X. and Thompson, P.M. et al., 2009

12. AD (N=104) versus Normal (N=157) - Mean Atrophy Rates -
Hua, X. and Thompson, P.M. et al., 2009

13. MCI (N=254) versus Normal (N=157) - Mean Atrophy Rates -
Hua, X. and Thompson, P.M. et al., 2009

14. MCI Converters Lose Tissue Faster
Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR, Bernstein MA, Britson PJ, Ward CP, Borowski B, Trojanowski JQ, Shaw L, Fleisher AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2009). Alzheimer’s Disease Neuroimaging Initiative: A One-year Follow up Study Correlating Degenerative Rates, Biomarkers and Cognition, NeuroImage, 2009 Apr 15;45(3):

15. Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR, Bernstein MA, Britson PJ, Ward CP, Borowski B, Trojanowski JQ, Shaw L, Fleisher AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2009). Alzheimer’s Disease Neuroimaging Initiative: A One-year Follow up Study Correlating Degenerative Rates, Biomarkers and Cognition, NeuroImage, 2009 Apr 15;45(3):

16. Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR, Bernstein MA, Britson PJ, Ward CP, Borowski B, Trojanowski JQ, Shaw L, Fleisher AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2009). Alzheimer’s Disease Neuroimaging Initiative: A One-year Follow up Study Correlating Degenerative Rates, Biomarkers and Cognition, NeuroImage, 2009 Apr 15;45(3):

17. For drug trials, want to summarize change in a Region-of-interest (ROI)
Anatomical ROI based on temporal lobes
Statistical ROI derived from an independent training sample of 22 AD patients
Hua, X., Lee, S., Yanovsky, I., Leow, A.D., Chou, Y.Y., Ho, A.J., Gutman, B., Toga, A.W., Jack, C.R. Jr, Bernstein, M.A., Reiman, E.M., Harvey, D., Kornak, J., Schuff, N., Alexander, G.E., Fox, N.C., Weiner, M.W., Thompson, P.M. and the Alzheimer's Disease Neuroimaging Initiative, Optimizing Power to Track Brain Degeneration in Alzheimer's Disease and Mild Cognitive Impairment with Tensor-Based Morphometry: An ADNI Study of 515 Subjects. To be submitted to NeuroImage.

18. Statistical ROI reduces sample size by 15-50%; most helpful in MCI
Statistically-defined ROI outperforms the anatomically-defined temporal lobe ROI; extremely helpful in MCI, as it focuses on the part of the brain that is changing most* AD
MCI
TBM Designs
Stat-ROI
Temporal-ROI
sKL-MI S6L8 48 55 88 99
sKL-MI S9L5
(better for MCI) 52 72
85*
132
Hua, X., Lee, S., Yanovsky, I., Leow, A.D., Chou, Y.Y., Ho, A.J., Gutman, B., Toga, A.W., Jack, C.R. Jr, Bernstein, M.A., Reiman, E.M., Harvey, D., Kornak, J., Schuff, N., Alexander, G.E., Fox, N.C., Weiner, M.W., Thompson, P.M. and the Alzheimer's Disease Neuroimaging Initiative, Optimizing Power to Track Brain Degeneration in Alzheimer's Disease and Mild Cognitive Impairment with Tensor-Based Morphometry: An ADNI Study of 515 Subjects. To be submitted to NeuroImage.

19. Sample size estimates for a drug trial (= 48AD, 88 MCI) - does it matter what statistical threshold is used to define the region with greatest effect sizes for change?
Hua, X. and Thompson, P.M. et al., 2009

20. Estimated sample sizes (n80) - needed to detect a 25% reduction in the mean annual change with a two-sided test and a=0.05 at 80% power, for a two-arm study
Sum-of-boxes Clinical Dementia Rating (CDR) gives best power among the clinical scores, but the TBM method is 10 times better AD
MCI
Loss Rate %/yr 48 88
CDR-SB
408
796
ADAS-Cog
619
6797
MMSE
1078
3275
Hua, X., Lee, S., Yanovsky, I., Leow, A.D., Chou, Y.Y., Ho, A.J., Gutman, B., Toga, A.W., Jack, C.R. Jr, Bernstein, M.A., Reiman, E.M., Harvey, D., Kornak, J., Schuff, N., Alexander, G.E., Fox, N.C., Weiner, M.W., Thompson, P.M. and the Alzheimer's Disease Neuroimaging Initiative, Optimizing Power to Track Brain Degeneration in Alzheimer's Disease and Mild Cognitive Impairment with Tensor-Based Morphometry: An ADNI Study of 515 Subjects. To be submitted to NeuroImage.

21. Is power better at 3T?
1.5T
3 T

22. 1.5T average
3 T average

23. More of the brain showed AD-accelerated tissue loss at 3T than at 1
More of the brain showed AD-accelerated tissue loss at 3T than at 1.5 T but with slightly weaker effect size (24 AD vs. 35 CTLs scanned at both field strengths)
1.5 T
3 T
Ho, AJ., Hua, X., Lee, S., Leow, AD., Yanovsky, I., Gutman, B., Dinov, ID., Lepore, N., Stein, JL., Hojatkashani, C., Toga, AW., Jack, JR., Bernstein, MA., Reiman, EM., Harvey, D., Kornak, J., Schuff, N., Alexander, GE., Weiner, MW., Thompson, PM. Comparing 3 Tesla and 1.5 Tesla MRI for Tracking Alzheimer’s Disease Progression with Tensor-Based Morphometry.

24. Generated a statistical ROI for each field strength (slightly smaller at 3T)
1.5T ROI (darker gray) slightly larger than 3T ROI (lighter gray)
Ho, AJ., Hua, X., Lee, S., Leow, AD., Yanovsky, I., Gutman, B., Dinov, ID., Lepore, N., Stein, JL., Hojatkashani, C., Toga, AW., Jack, JR., Bernstein, MA., Reiman, EM., Harvey, D., Kornak, J., Schuff, Norbert., Alexander, GE., Weiner, MW., Thompson, PM. Comparing 3 Tesla and 1.5 Tesla MRI for Tracking Alzheimer’s Disease Progression with Tensor-Based Morphometry.

25. MCI: Power slightly worse at 3T, similar in AD
1.5 Tesla 37
107
3 Tesla 48
159
Very similar in AD
Worse for MCI
N80 = Minimal Sample Sizes, per diagnostic group, to detect 25% slowing of the mean atrophic rate (with 80% power, alpha = 0.05).
Ho, AJ., Hua, X., Lee, S., Leow, AD., Yanovsky, I., Gutman, B., Dinov, ID., Lepore, N., Stein, JL., Hojatkashani, C., Toga, AW., Jack, JR., Bernstein, MA., Reiman, EM., Harvey, D., Kornak, J., Schuff, Norbert., Alexander, GE., Weiner, MW., Thompson, PM. Comparing 3 Tesla and 1.5 Tesla MRI for Tracking Alzheimer’s Disease Progression with Tensor-Based Morphometry.

26. Mixing 3T and 1.5T scanners - Power did not degrade at all when 25% of the scanners were 3T
3T ONLY
159
1.5T ONLY
134
134
103
107 48 58 52 37 37
MIX IS OK
Ho, AJ., Hua, X., Lee, S., Leow, AD., Yanovsky, I., Gutman, B., Dinov, ID., Lepore, N., Stein, JL., Hojatkashani, C., Toga, AW., Jack, JR., Bernstein, MA., Reiman, EM., Harvey, D., Kornak, J., Schuff, Norbert., Alexander, GE., Weiner, MW., Thompson, PM. Comparing 3 Tesla and 1.5 Tesla MRI for Tracking Alzheimer’s Disease Progression with Tensor-Based Morphometry.

27. Morra JH, Tu Z, Apostolova LG, Green A, Toga AW, Thompson PM (2009)
Morra JH, Tu Z, Apostolova LG, Green A, Toga AW, Thompson PM (2009). Comparison of Adaboost and Support Vector Machines for Detecting Alzheimer’s Disease through Automated Hippocampal Segmentation, IEEE Transactions on Medical Imaging, in press.

29. Morra JH, Tu Z, Apostolova LG, Green A, Toga AW, Thompson PM (2009)
Morra JH, Tu Z, Apostolova LG, Green A, Toga AW, Thompson PM (2009). Comparison of Adaboost and Support Vector Machines for Detecting Alzheimer’s Disease through Automated Hippocampal Segmentation, IEEE Transactions on Medical Imaging, in press.

30. HP Loss Rates (980 scans)
The real power is to detect change over time because this is both a subtle and specific measure. We want to measure how individuals (or groups) respond to treatment therefore we need a relatively consistent segmentation or else this won’t be of much use.
Every bar is significant except the normal right (p = 0.983). Therefore these two groups are too close to call. This suggests the disease affects the left, then the right, then the left hippocampi (judging by bar sizes).
Morra, J., Tu, Z., Apostolova, L.G., Green, A., Avedissian, C., Madsen, S., Parikshak, N., Hua, X., Toga, A., Jack, C., Schuff, N., Weiner, M., Thompson, P., Automated Mapping of Hippocampal Atrophy in 1-Year Repeat MRI Data in 490 Subjects with Alzheimer’s Disease, Mild Cognitive Impairment, and Elderly Controls. Neuroimage. 30

31. ApoE4+ atrophied 2-3% faster
The real power is to detect change over time because this is both a subtle and specific measure. We want to measure how individuals (or groups) respond to treatment therefore we need a relatively consistent segmentation or else this won’t be of much use.
Every bar is significant except the normal right (p = 0.983). Therefore these two groups are too close to call. This suggests the disease affects the left, then the right, then the left hippocampi (judging by bar sizes).
Morra, J., Tu, Z., Apostolova, L.G., Green, A., Avedissian, C., Madsen, S., Parikshak, N., Hua, X., Toga, A., Jack, C., Schuff, N., Weiner, M., Thompson, P., Automated Mapping of Hippocampal Atrophy in 1-Year Repeat MRI Data in 490 Subjects with Alzheimer’s Disease, Mild Cognitive Impairment, and Elderly Controls. Neuroimage. 31

32. AT BASELINE, GROUP DIFFERENCES ARE MAPPED:
Morra, J., Tu, Z., Apostolova, L.G., Green, A., Avedissian, C., Madsen, S., Parikshak, N., Hua, X., Toga, A., Jack, C., Schuff, N., Weiner, M., Thompson, P., Automated Mapping of Hippocampal Atrophy in 1-Year Repeat MRI Data in 490 Subjects with Alzheimer’s Disease, Mild Cognitive Impairment, and Elderly Controls. Neuroimage. 32

33. Significance Maps 33

34. BASELINE ATROPHY CORRELATES WITH:
Significance Maps 34

35. Significance Maps 35

36. 36

39. 39

40. 40

41. 41

42. Chou YY, Leporé N, Avedissian C, Madsen S, Parikshak N, Hua X, Trojanowski J, Shaw L, Weiner M, Toga A, Thompson PM (2009). Mapping Correlations between Ventricular Expansion, and CSF Amyloid & Tau Biomarkers in 240 Subjects with Alzheimer’s Disease, Mild Cognitive Impairment & Elderly Controls, NeuroImage Feb 21. 42

43. Chou YY, Leporé N, Avedissian C, Madsen SK, Parikshak N, Hua X, Trojanowski JQ, Shaw L, Weiner MW, Toga AW, Thompson PM (2009). Mapping Correlations between Ventricular Expansion, and CSF Amyloid & Tau Biomarkers in 240 Subjects with Alzheimer’s Disease, Mild Cognitive Impairment and Elderly Controls, NeuroImage Feb 21. [Epub ahead of print] 43

44. Summary
All MRI measures correlate well with CSF biomarkers, clinical decline, and predict future conversion to AD.
TBM needs 50 AD and 75 MCI subjects to detect 25% slowing of disease (10x better than best clinical score)
All maps show focal effects - interesting that these statistically guided ROIs will give much better numeric summaries of change (15-50% reductions in sample size)
Mixing 1.5T and 3T scanners is not a problem; but 3T was slightly worse for tracking change in MCI